Aytu BioScience, Inc., a specialty healthcare company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and ZolpiMist, an oral spray for the treatment of insomnia. It also offers MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. In addition, the company provides MiOXSYS analyzer, a portable lightweight desktop platform that is used in clinical or research laboratory or near a patient care area; and MiOXSYS disposable sensors. The company is based in Englewood, Colorado.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone720-437-6580
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.32 million
Profitability
Miscellaneous
Employees52
Next Earnings Date2/6/2020 (Estimated)
OptionableNot Optionable
Aytu Bioscience (NASDAQ:AYTU) Frequently Asked Questions
What is Aytu Bioscience's stock symbol?
Aytu Bioscience trades on the NASDAQ under the ticker symbol "AYTU."
When did Aytu Bioscience's stock split? How did Aytu Bioscience's stock split work?
Shares of Aytu Bioscience reverse split before market open on Tuesday, August 29th 2017. The 1-20 reverse split was announced on Friday, August 25th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 28th 2017. An investor that had 100 shares of Aytu Bioscience stock prior to the reverse split would have 5 shares after the split.
How were Aytu Bioscience's earnings last quarter?
Aytu Bioscience Inc (NASDAQ:AYTU) released its earnings results on Thursday, November, 14th. The company reported ($0.32) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.30) by $0.02. The business earned $1.44 million during the quarter, compared to analyst estimates of $1.45 million. Aytu Bioscience had a negative return on equity of 252.42% and a negative net margin of 390.43%. View Aytu Bioscience's Earnings History.
When is Aytu Bioscience's next earnings date?
What price target have analysts set for AYTU?
1 analysts have issued 12 month price objectives for Aytu Bioscience's stock. Their forecasts range from $4.75 to $5.00. On average, they expect Aytu Bioscience's stock price to reach $4.88 in the next year. This suggests a possible upside of 494.5% from the stock's current price. View Analyst Price Targets for Aytu Bioscience.
What is the consensus analysts' recommendation for Aytu Bioscience?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aytu Bioscience in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Aytu Bioscience.
What are Wall Street analysts saying about Aytu Bioscience stock?
Here are some recent quotes from research analysts about Aytu Bioscience stock:
- 1. According to Zacks Investment Research, "Aytu BioScience, Inc. is a healthcare company which focused on commercialization of novel products in the field of urology. The company's marketed products consists of ProstaScint(R), Primsol(R) and MiOXSYS(TM) which addresses prostate cancer, urinary tract infections, male infertility and male sexual dysfunction. Aytu BioScience, Inc. is based in Englewood, Colorado. " (1/15/2020)
- 2. Northland Securities analysts commented, "We perceive the co-promotion agreement positively as significantly enhances direct selling of Natesto while placing a higher promotional focus on urologists and endocrinologists. Pre-open, Aytu BioScience announced that it amended its agreement with Acerus Pharmaceuticals, wherein Natesto (testosterone nasal gel spray for the treatment of Low-T) will be co-promoted with Acerus Pharamceuticals. Under the terms of the amended agreement and upon closing, Acerus Pharmaceuticals will launch a complementary US commercial team of at least 25 US-based specialty sales reps that will market Natesto directly to urologists and endocrinologists. This will nearly double the size of the Natesto field salesforce." (7/30/2019)
Has Aytu Bioscience been receiving favorable news coverage?
News stories about AYTU stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Aytu Bioscience earned a media sentiment score of 1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Aytu Bioscience.
Are investors shorting Aytu Bioscience?
Aytu Bioscience saw a increase in short interest in December. As of December 31st, there was short interest totalling 735,800 shares, an increase of 75.1% from the December 15th total of 420,100 shares. Based on an average daily volume of 125,500 shares, the short-interest ratio is currently 5.9 days. Approximately 4.5% of the shares of the company are sold short. View Aytu Bioscience's Current Options Chain.
Who are some of Aytu Bioscience's key competitors?
Some companies that are related to Aytu Bioscience include AgeX Therapeutics (AGE), Tiziana Life Sciences (TLSA), Checkpoint Therapeutics (CKPT), CNS Pharmaceuticals (CNSP), Chembio Diagnostics (CEMI), Infinity Pharmaceuticals (INFI), Entasis Therapeutics (ETTX), Alpine Immune Sciences (ALPN), Acasti Pharma (ACST), Kezar Life Sciences (KZR), SCYNEXIS (SCYX), Sunesis Pharmaceuticals (SNSS), American Brivision (Holding) (ABVC), Onconova Therapeutics (ONTX) and resTORbio (TORC).
What other stocks do shareholders of Aytu Bioscience own?
Who are Aytu Bioscience's key executives?
Aytu Bioscience's management team includes the folowing people:
- Mr. Joshua R. Disbrow, Chairman & CEO (Age 44)
- Mr. David A. Green, CFO, Sec. & Treasurer (Age 56)
- Mr. Jarrett T. Disbrow, Chief Operating Officer (Age 44)
Who are Aytu Bioscience's major shareholders?
Aytu Bioscience's stock is owned by a number of of retail and institutional investors. Top institutional investors include Searle & CO. (1.31%). Company insiders that own Aytu Bioscience stock include Armistice Capital Master Fund, David A Green, Jarrett Disbrow and Joshua R Disbrow. View Institutional Ownership Trends for Aytu Bioscience.
Which institutional investors are buying Aytu Bioscience stock?
AYTU stock was acquired by a variety of institutional investors in the last quarter, including Searle & CO.. Company insiders that have bought Aytu Bioscience stock in the last two years include Armistice Capital Master Fund, David A Green, Jarrett Disbrow and Joshua R Disbrow. View Insider Buying and Selling for Aytu Bioscience.
How do I buy shares of Aytu Bioscience?
Shares of AYTU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Aytu Bioscience's stock price today?
One share of AYTU stock can currently be purchased for approximately $0.82.
How big of a company is Aytu Bioscience?
Aytu Bioscience has a market capitalization of $17.00 million and generates $7.32 million in revenue each year. The company earns $-27,130,000.00 in net income (profit) each year or ($3.48) on an earnings per share basis. Aytu Bioscience employs 52 workers across the globe.View Additional Information About Aytu Bioscience.
What is Aytu Bioscience's official website?
How can I contact Aytu Bioscience?
Aytu Bioscience's mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-437-6580 or via email at [email protected]
MarketBeat Community Rating for Aytu Bioscience (NASDAQ AYTU)
MarketBeat's community ratings are surveys of what our community members think about Aytu Bioscience and other stocks. Vote "Outperform" if you believe AYTU will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AYTU will underperform the S&P 500 over the long term. You may vote once every thirty days.
